OTCMKTS:HKMPF - Hikma Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$19.25 0.00 (0.00 %)
(As of 07/16/2018 08:34 AM ET)
Previous Close$19.25
Today's Range$19.25 - $19.25
52-Week Range$12.00 - $19.50
VolumeN/A
Average Volume63 shs
Market Capitalization$4.64 billion
P/E Ratio18.33
Dividend Yield0.57%
Beta-1.23
Hikma Pharmaceuticals logoHikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Receive HKMPF News and Ratings via Email

Sign-up to receive the latest news and ratings for HKMPF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Private households
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:HKMPF
CUSIPN/A
Phone44-20-7399-2760

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio18.33
Forward P/E Ratio21.15
P/E Growth6.94

Sales & Book Value

Annual Sales$1.94 billion
Price / Sales2.40
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees8,500
Outstanding Shares240,870,000
Market Cap$4,636.69

The Truth About Cryptocurrencies

Hikma Pharmaceuticals (OTCMKTS:HKMPF) Frequently Asked Questions

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPF."

What is the consensus analysts' recommendation for Hikma Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Hikma Pharmaceuticals' key competitors?

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the folowing people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 61)
  • Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 60)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 49)
  • Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 46)
  • Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

Has Hikma Pharmaceuticals been receiving favorable news coverage?

News coverage about HKMPF stock has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Hikma Pharmaceuticals earned a media sentiment score of 0.15 on Accern's scale. They also gave media stories about the company an impact score of 46.03 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPF stock can currently be purchased for approximately $19.25.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of $4.64 billion and generates $1.94 billion in revenue each year. Hikma Pharmaceuticals employs 8,500 workers across the globe.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company can be reached via phone at 44-20-7399-2760 or via email at [email protected]


MarketBeat Community Rating for Hikma Pharmaceuticals (OTCMKTS HKMPF)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  125
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HKMPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HKMPF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.